An Study of Aripiprazole in the Treatment of Methamphetamine Dependence
NCT ID: NCT01813656
Last Updated: 2015-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
10 participants
INTERVENTIONAL
2012-09-30
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence
NCT01825928
Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial
NCT00728312
Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients
NCT00780702
Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
NCT00089440
Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)
NCT01888835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aripiprazole
Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
Aripiprazole
Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
Sugar pill
placebo arm,5mg/pill,10mg/day,last12weeks
placebo
placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aripiprazole
Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
placebo
placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must sign a Information consent form.
3. Required to provide detailed address and phone number
Exclusion Criteria
2. Suicide ideation or hurt others.
3. Taking antipsychotic within two weeks before.
4. drug allergy to Risperidone or Aripiprazole.
5. pregnancy and breastfeeding women.
19 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wei Hao
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wei Hao
The Second Xiangya Hospital of Cental South University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wei Hao, MD., Ph.D.
Role: STUDY_DIRECTOR
Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Xiangya Hospital of Central University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
100000-068942
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.